Optogenetic gene therapy is safe in 10 people blinded by retinitis pigmentosa, NEJM trial finds
Optogenetic gene therapy was safe in 10 blind people with advanced retinitis pigmentosa, six of whom gained clinically meaningful light sensitivity. The gains were measured within each patient in a small dose-escalation study, so the result supports safety and shows the approach works in people while sharp vision stays years away.
The Scientist · Science desk
Two bars covering all 10 participants: 7 had increased light sensitivity in vision tests, and 3 did not show increased light sensitivity.
Participants out of 10, by vision-test result In participants
| Item | Value | Claim |
|---|---|---|
| Increased light sensitivity | 7 participants | 9 |
| No increase in light sensitivity | 3 participants | 24 |
What happened
- The NEJM study extends a 2021 single-patient result to 10 participants, including that first patient, in work led by José-Alain Sahel of Pittsburgh and Botond Roska of IOB Basel.
- Each participant had one injection in the worse-seeing eye of a gene for ChrimsonR, an amber-sensitive protein, at one of three escalating doses.
- Researchers logged 33 mild or moderate eye events in nine participants, such as temporary inflammation and raised eye pressure, plus one severe event that cleared within minutes.
- The results appeared in the same week that optogenetics, the technique of controlling neurons with light, won its inventors the 2026 Nobel Prize in Physiology or Medicine.
Why it matters
- What's now possible capability Because the therapy bypasses the photoreceptors, Sahel says it could help patients whichever of the hundreds of genes behind retinitis pigmentosa is mutated, so one treatment could cover a disease with many genetic causes.
- What it limits constraint The treated ganglion cells form a ring around the fovea, the pit responsible for sharp central vision, so patients can detect objects but, Roska said, cannot yet detect faces.
- What it sets up precedent Oxford's Mark Hankins said the results reassure on safety for people who still have some residual vision. Treating that group would take the approach beyond the blind patients enrolled here.
Next story · Science · Oct 7
Optogenetic gene therapy improves light sensitivity in 7 of 10 people blinded by retinitis pigmentosaConfirmed2 publishers
The most carefully controlled comparison in the paper involves a tumbler. In five patients, the team recorded EEG while each tried to detect a tumbler placed in front of them, with and without the goggles, eyes open and eyes closed [18]. Decoding accuracy rose with the goggles only when the eyes were open [18]. If the goggles had been generating the signal by themselves, closing the eyes would have made no difference. The authors take the result as a genuine change in visual processing [18].
The behavioural results rest on fewer people than the trial's headline count. Eight participants did the object tasks [10]. Five of them were more accurate at finding and touching a notebook with the goggles on. Four improved on a staple-box task, and five did better at judging the orientation of a single bar [10]. In a second EEG test, passive viewing of periodic stimuli, decoding accuracy also rose, and that gain correlated with average improvement on the notebook and staple-box tasks [19].
Response varied widely. Among the seven whose light sensitivity rose, the largest gain was about 31 times the smallest [25], and three participants did not improve [24]. Doses spanned a factor of 10 across the three groups [26]. Neither published account breaks the responses down by dose group, so these reports cannot tell us whether dose explains the spread. The Guardian reported that participants who spent more time training with the goggles tended to do better on the tasks [11]. That is an association. Patients who saw more through the goggles may simply have chosen to wear them longer.
Safety was the primary aim [6]. The 33 eye events average about 3.7 for each of the nine people who had one [27], and the Guardian reported no therapy-related side effects elsewhere in the body [8]. The authors concluded the treatment was safe within the limits of the study [7]. Ten people are enough to show that common harms are mild but too few to rule out rare ones. We think the safety record is still strong enough to justify a larger trial.
The therapy works on cells the disease spares. "The therapy bypasses the damaged photoreceptors and takes advantage of retinal circuits that remain intact," said Sahel [13]. The injected gene makes surviving retinal ganglion cells respond to light, and the goggles supply that light. A camera tracks changes in intensity pixel by pixel and converts them into amber pulses aimed at ChrimsonR [16]. The wearer perceives a monochrome image, according to the Guardian [17].
Roska kept the claim narrow. "What we can say for sure is that the concept of optogenetics is valid for vision restoration," he said [20]. He hopes to reach high-resolution vision in five to 10 years [28]. Mark Hankins, professor of visual neuroscience at the University of Oxford, who was not involved, pointed to how long the effect has lasted: "we've seen that we can give a stable restoration of some visual function, some light sensitivity, that lasts for four or five years in these patients," he said [23]. "They're baby steps, but they're critical," he said [22].
What to watch
- A dose-group breakdown of the light-sensitivity gains, to test whether the roughly 31-fold spread between responders follows the tenfold dose range.
- A trial with an untreated or sham-injected comparison group measuring task performance, evidence that the within-patient tests here cannot supply.
- Follow-up beyond five years, to see whether the stable gains Hankins described hold up.
Clarity's read
What the record supports and how the coverage leans. The claims behind it follow.
Reality
- Evidence60
- Adoption
- Not scored
- Hype gap+15
- Incentives
- Not scored
- Confidence65
Claim ledger
Ranked by verification strength, evidence, and original report placement.
- [1]
In a first-in-human study in 2021, a collaboration led by José-Alain Sahel of the University of Pittsburgh School of Medicine and Botond Roska of the Institute of Molecular and Clinical Ophthalmology Basel (IOB) showed optogenetic therapy led to partial recovery of visual function in a blind patient with retinitis pigmentosa.
- [2]
Researchers reported results from a larger trial, published in the New England Journal of Medicine, involving the original 2021 patient and a further nine people.
- [3]
Optogenetics, a method that uses light to characterize and manipulate the activity of neurons, earlier this week won its inventors the 2026 Nobel Prize in Physiology or Medicine.
- [4]
10 participants with blindness due to advanced retinitis pigmentosa were injected in their worse-seeing eye with a gene that produces ChrimsonR, a light-sensitive protein with a peak response at around 590 nm (amber).
- [5]
Subjects were divided into three dose-escalation groups receiving 5.0 x 10^10, 1.5 x 10^11 or 5.0 x 10^11 vector genomes per eye.
- [6]
The primary aim was safety. Researchers observed 33 mild and moderate adverse ocular events in nine of the participants, such as temporary inflammation and increases in eye pressure, plus one severe event which resolved within minutes after treatment.
- [7]
The researchers concluded that, within the limits of the study, the treatment was safe.
- [8]
There were no side effects related to the therapy in the rest of the body.
- [9]
Vision tests revealed the treatment increased light sensitivity in seven of the 10 participants, by a factor of 2.0 to 62.3, with six patients showing a clinically meaningful improvement.
- [10]
In the notebook task, five of eight participants had higher accuracy with the goggles than without; four showed improved accuracy in the staple-box task; in a single-bar orientation task, accuracy was higher with goggles in five of eight participants.
- [11]
The team said participants who spent more time training with the goggles tended to do better on the tasks.
- [12]
"[Patients] can detect objects, but they cannot yet detect faces," said Roska; the team attributes this to the treated ganglion cells being in a ring-like arrangement around the fovea, the pit in the retina responsible for sharp central vision.
- [13]
"The therapy bypasses the damaged photoreceptors and takes advantage of retinal circuits that remain intact," Sahel said.
- [14]
Sahel notes retinitis pigmentosa can be caused by mutations in any one of hundreds of different genes, and optogenetic therapy can potentially help regardless of the underlying mutation.
- [15]
Participants' outcomes were followed for up to five years.
- [16]
The goggles contain a camera that detects changes in light intensity pixel by pixel and converts the data into pulses of amber light projected onto the eye to activate ChrimsonR in the modified retinal ganglion cells.
- [17]
The light pulses activate the light-sensitised ganglion cells, allowing the wearer to perceive a monochrome image.
- [18]
EEG recordings were obtained in five patients. In a tumbler detection test, EEG decoding accuracy was higher with goggles than without when the eyes were open but not when they were closed, implying a genuine improvement in visual processing rather than an artefact.
- [19]
A second EEG test, passive viewing of periodic visual stimuli, also showed increased decoding accuracy, which correlated with mean improvements in the notebook and staple-box tasks.
- [20]
"What we can say for sure is that the concept of optogenetics is valid for vision restoration," said Prof Botond Roska.
- [21]
Mark Hankins, professor of Visual Neuroscience at the University of Oxford, not involved in the work, said the study provides reassurance on the safety of the approach and its application to people who still have some residual vision.
- [22]
"They're baby steps, but they're critical," said Mark Hankins.
- [23]
"we've seen that we can give a stable restoration of some visual function, some light sensitivity, that lasts for four or five years in these patients," said Mark Hankins.
- [24]
Three of the 10 participants did not show increased light sensitivity.
- [25]
The largest light-sensitivity gain was about 31 times the smallest among the seven responders.
- [26]
The highest dose was 10 times the lowest.
- [27]
The 33 mild or moderate eye events average about 3.7 per affected participant.
- [28]
Roska said the aim is now to work towards restoring high-resolution vision, with the hope of achieving the goal in five to 10 years.
Sources
2 independent publishers whose own reporting we read for this story.
- physicsworld.comOptogenetic therapy shows promise for vision restoration
1 article · October 8, 2026
- theguardian.comGene therapy can partly restore sight in blind people, researchers reveal
1 article · October 7, 2026
Topics and entities
Topics
- Vision restoration therapy
- Optogenetics
- Retinitis pigmentosa
- Gene therapy
Entities
- New England Journal of Medicine
- Valentina Emiliani
- Institute of Molecular and Clinical Ophthalmology Basel
- Institut de la Vision
- José-Alain Sahel
- UPMC Vision Institute